Iovance Biotherapeutics, Inc.（股票代码：IOVA）今日盘中大涨22.44%，引起了市场的广泛关注。
消息面上，公司近日宣布，其针对软组织肉瘤的肿瘤浸润淋巴细胞（TIL）疗法在首次临床试验中取得了积极成果。这一突破性进展标志着TIL细胞疗法在实体瘤治疗领域迈出了关键一步，为患者带来了新的治疗希望，也显著增强了投资者对公司研发管线未来潜力的信心。
此外，公司公布的数据显示，其核心疗法Lifileucel展现出良好的安全性特征，且该特征与疗法在其他适应症中观察到的数据保持一致，进一步支持了其潜在的治疗价值。同时，公司计划于2026年第二季度启动一项针对二线治疗后的晚期未分化多形性肉瘤（UPS）和去分化脂肪肉瘤（DDLPS）患者的单臂注册临床试验，这加速了疗法的注册进程。这些积极的临床数据和研发进展共同构成了推动股价在盘中交易中强劲上扬的主要动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.